Economic Evaluation of Add-on Levetiracetam for the Treatment of Refractory Partial Epilepsy in Korea
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objective: This study estimated the expected cost-effectiveness ratio expressed as the incremental cost per seizure-free day (SFD) gained and the incremental cost per quality adjusted life year (QALY) gained when using levetiracetam (LEV) as add-on therapy from a third-party payer perspective. Methods: A 1-year dose-escalation decision-tree model comparing LEV plus standard therapy (ST) with ST alone was designed to combine transition probabilities, costs and outcomes. The short-term outcomes and probabilities were derived from a prospective, openlabel clinical trial with 100 Korean adults with refractory partial epilepsy. All data for the direct medical costs were derived from Korean cost data extracted from reports published by the National Health Insurance Corporation. Results: The average gain in SFDs attributed to LEV add-on was 18.3 days per patient per year and the incremental cost-effectiveness ratios (ICERs) for LEV add-on were US$ 44 per SFD per patient and US$ 11,084 per QALY gained. All sensitivity analyses showed that the model was robust to the assumptions made. Conclusion: The economic evaluation indicates that, given a wide range of assumptions, the increased cost of treating patients having refractory partial epilepsy with LEV may be partially offset by a reduction in other direct medical costs. This reduction is a consequence of an increase in the number of SFDs and improved quality of life.
Abstract
Objective: This study estimated the expected cost-effectiveness ratio expressed as the incremental cost per seizure-free day (SFD) gained and the incremental cost per quality adjusted life year (QALY) gained when using levetiracetam (LEV) as add-on therapy from a third-party payer perspective. Methods: A 1-year dose-escalation decision-tree model comparing LEV plus standard therapy (ST) with ST alone was designed to combine transition probabilities, costs and outcomes. The short-term outcomes and probabilities were derived from a prospective, openlabel clinical trial with 100 Korean adults with refractory partial epilepsy. All data for the direct medical costs were derived from Korean cost data extracted from reports published by the National Health Insurance Corporation. Results: The average gain in SFDs attributed to LEV add-on was 18.3 days per patient per year and the incremental cost-effectiveness ratios (ICERs) for LEV add-on were US$ 44 per SFD per patient and US$ 11,084 per QALY gained. All sensitivity analyses showed that the model was robust to the assumptions made. Conclusion: The economic evaluation indicates that, given a wide range of assumptions, the increased cost of treating patients having refractory partial epilepsy with LEV may be partially offset by a reduction in other direct medical costs. This reduction is a consequence of an increase in the number of SFDs and improved quality of life.
참고문헌 (27)
- Sander JW, "Epidemiology of the epilepsies", J Neurol Neurosurg and Psychiatry, 61, pp.433~443 (1996)
- Cockerell OC, "Remission of epilepsy: results from the National General Practice Study of Epilepsy", Lancet, 346, pp.140~144 (1995)
- Proposal for revised classification of epilepsies and epileptic syndromes, "Commission on Classification and Terminology of the Inter national League Against Epilepsy", Epilepsia, 30, pp.389~399 (1989)
- Ben-Menachem E, "Efficacy and tolerability of levetiracetam 3,000 mg", d in patients with refractory partial seizures: a multicentre, double-blind, responder-selected study evaluating monotherapy. European Levetiracetam Study Group, 2000, pp.41, 1276~1283
- Cereghino JJ, "Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial", Neurology, 55, pp.236~242 (2000)
- Shorvon SD, "Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. European Levetiracetam Study Group", Epilepsia, 41, pp.1179~1186 (2000)
- Patsalos PN, "LEV: Chemistry, biotransformation, pharmacokinetics, and drug interactions. in: Antiepileptic Drugs", pp.428~432 (2002), Lippincott Williams & Wilkins
- Perucca E, "The ideal pharmacokinetic properties of an antiepileptic drug: how close does levetiracetam come?", Epileptic Disorders, 5, pp.S17~S26 (2003)
- Zhao Q, "Single-dose pharmacokinetics of levetiracetam in healthy Chinese male subjects", Br J Clin Pharmacol, 63, pp.614~617 (2007)
- Pigeolet E, "Population pharmacokinetics of levetiracetam in Japanese and Western adults", Clin Pharmacokinet, 46, pp.503~512 (2007)
- Luce BR, "Standards for the Socioeconomic Evaluation of Health of Health Care Services" (1990), Springer-Verlag
- Heo K, "Efficacy and safety of levetiracetam as adjunctive treatment of refractory partial seizures in a multicentre open-label single-arm trial in Korean patients", Seizure, 16, pp.402~409 (2007)
- Cramer JA, "Development and cross-cultural translations of a 31-item quality of life in epilepsy inventory", Epilepsia, 39, pp.81~88 (1998)
- May TW, "Psychometric properties of the German translation of the QOLIE-31", Epilepsy & Behav, 2, pp.106~114 (2001)
- Beghi E, "Validity and reliability of the Italian version of the Quality-of-Life in Epilepsy Inventory (QOLIE-31)", Seizure, 14, pp.452~458 (2005)
- Piperidou H, "The Greek version of the Quality of Life in Epilepsy Inventory (QOLIE-31)", Qual Life Res, 15, pp.833~839 (2006)
- Devinsky O, "Development of the quality of life in epilepsy inventory", Epilepsia, 36, pp.1089~1104 (1995)
- Meencke HJ, "Assessment of a dose-response relationship of levetiracetam", Eur J Neurol, 13, pp.942~946 (2006)
- Blais L, "Economic evaluation of levetiracetam as an add-on therapy in patients with refractory epilepsy", Pharmacoeconomics, 23, pp.493~503 (2005)
- National Health Insurance Corporation, "2006 National Health Insurance Statistical Yearbook" (2007), National Health Insurance Corporation
- National Health Insurance Corporation, "Major Health Insurance statistics", Health Insurance Forum, 5, pp.146~150 (2006)
- Markowitz MA, "Cost-effectiveness model of adjunctive lamotrigine for the treatment of epilepsy", Neurology, 51, pp.1026~1033 (1995)
- LeLorier J, "Levetiracetam: an innovative and cost-effective add-on drug for refractory partial epilepsy", Expert Review of Pharmacoeconomics and Outcomes Research, 4, pp.143~151 (2004)
- Schachter SC, "A cost-effectiveness analysis of tiagabine, phenytoin, and carbamazepine adjunctive therapy for patients with complex partial seizure", Neurology, 52(6), pp.A143~ (1999)
- Messori A, "Adjunctive lamotrigine therapy in patients with refractory seizures:a lifetime cost-utility analysis", Eur J Clin Pharmacol, 53, pp.421~427 (1998)
- Mortimer D, "Comparing the incomparable? A systematic review of competing techniques for converting descriptive measures of health status into QALY-weights", Med Decis Making, 28, pp.66~89 (2008)
- Jo MW, "Estimating quality weights for EQ-5D health states with the time trade-off method in South Korea", Value in Health, 11, pp.1186~1189 (2008)